|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
61,890,000 |
Market
Cap: |
N/A |
Last
Volume: |
2,615,875 |
Avg
Vol: |
1,192,496 |
52
Week Range: |
$7.07 - $7.07 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Related Products |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Angotti Vincent |
SVP & CCO |
|
2010-08-10 |
4 |
D |
$6.37 |
$5,688 |
D/D |
(893) |
7,011 |
|
- |
|
Angotti Vincent |
SVP & CCO |
|
2010-08-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
7,904 |
|
- |
|
Stamler David A |
SVP, Chief Medical Officer |
|
2010-08-02 |
4 |
D |
$6.18 |
$5,519 |
D/D |
(893) |
7,563 |
|
- |
|
Stamler David A |
SVP, Chief Medical Officer |
|
2010-08-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
8,456 |
|
- |
|
Harris William G |
SVP, Finance and CFO |
|
2010-02-24 |
4 |
D |
$8.02 |
$4,772 |
D/D |
(595) |
35,605 |
|
- |
|
Harris William G |
SVP, Finance and CFO |
|
2010-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,667 |
36,200 |
|
- |
|
Barrett Ronald W |
Chief Executive Officer |
|
2010-02-24 |
4 |
D |
$8.02 |
$35,833 |
D/D |
(4,468) |
29,960 |
|
- |
|
Barrett Ronald W |
Chief Executive Officer |
|
2010-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,500 |
34,428 |
|
- |
|
Savello David R |
SVP, Development |
|
2010-02-24 |
4 |
D |
$8.02 |
$23,892 |
D/D |
(2,979) |
26,623 |
|
- |
|
Savello David R |
SVP, Development |
|
2010-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,335 |
26,921 |
|
- |
|
Rieflin William Jl |
President |
|
2010-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,917 |
21,106 |
|
- |
|
Gallop Mark A |
SVP, Research |
|
2010-02-24 |
4 |
D |
$8.02 |
$4,772 |
D/D |
(595) |
20,804 |
|
- |
|
Gallop Mark A |
SVP, Research |
|
2010-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,667 |
21,399 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2010-02-24 |
4 |
D |
$8.02 |
$5,975 |
D/D |
(745) |
16,201 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2010-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,085 |
16,946 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2010-02-01 |
4 |
AS |
$18.30 |
$37,025 |
D/D |
(2,000) |
14,861 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2010-02-01 |
4 |
OE |
$1.50 |
$3,000 |
D/D |
2,000 |
16,861 |
|
- |
|
Barrett Ronald W |
Chief Executive Officer |
|
2010-02-01 |
4 |
D |
$18.50 |
$9,953 |
D/D |
(538) |
21,928 |
|
- |
|
Barrett Ronald W |
Chief Executive Officer |
|
2010-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,250 |
22,466 |
|
- |
|
Rieflin William Jl |
President |
|
2010-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,250 |
18,189 |
|
- |
|
Harris William G |
SVP, Finance and CFO |
|
2010-02-01 |
4 |
D |
$18.50 |
$3,978 |
D/D |
(215) |
34,533 |
|
- |
|
Harris William G |
SVP, Finance and CFO |
|
2010-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
500 |
34,748 |
|
- |
|
Gallop Mark A |
SVP, Research |
|
2010-02-01 |
4 |
D |
$18.50 |
$3,978 |
D/D |
(215) |
19,732 |
|
- |
|
Gallop Mark A |
SVP, Research |
|
2010-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
500 |
19,947 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2010-02-01 |
4 |
D |
$18.50 |
$4,977 |
D/D |
(269) |
14,861 |
|
- |
|
663 Records found
|
|
Page 13 of 27 |
|
|